2026-06-14T03:32:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/91542025-04-01T10:57:29Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16959col_20.500.12105_16962col_20.500.12105_16964col_20.500.12105_16968col_20.500.12105_16970col_20.500.12105_16974col_20.500.12105_16975col_20.500.12105_16981col_20.500.12105_16983

00925njm 22002777a 4500 dc Ibáñez-Sanz, Gemma author Díez-Villanueva, Anna author Vilorio-Marqués, Laura author Gracia, Esther author Aragones, Nuria author Olmedo-Requena, Rocío author Llorca, Javier author Vidán, Juana author Amiano, Pilar author Nos, Pilar author Fernández-Tardón, Guillermo author Rada, Ricardo author Chirlaque, María-Dolores author Guinó, Elisabet author Dávila-Batista, Verónica author Castaño-Vinyals, Gemma author Perez-Gomez, Beatriz author Mirón-Pozo, Benito author Dierssen-Sotos, Trinidad author Etxeberria, Jaione author Molinuevo, Amaia author Álvarez-Cuenllas, Begoña author Kogevinas, Manolis author Pollan-Santamaria, Marina author Moreno, Victor author 2018 A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs. Sci Rep. 2018 Feb 1;8(1):2040. 10.1038/s41598-018-20349-6 2045-2322 2045-2322 Scientific reports 29391578 http://hdl.handle.net/20.500.12105/9154 Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study